Research Index
Semaglutide Research Index
PSI surfaces 50 peer-reviewed studies on Semaglutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes.
Hoog MM, Vallarino C, Maldonado JM et al.
J Manag Care Spec Pharm·2026·Human·Glycemic Control, Weight Loss·PubMed →
Semaglutide for Treating Paediatric Craniopharyngioma-Related Obesity: A Multicentre Case Series.
Dornberger J, Barat P, Aouchiche K et al.
Diabetes Obes Metab·2026·Human·PubMed →
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
Ciudin A, Johansson E, Zimner-Rapuch S et al.
Int J Obes (Lond)·2026·Human·PubMed →
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia.
Alharajin R, AlTaweel M, AlSubaiee M et al.
J ASEAN Fed Endocr Soc·2026·Human·Glycemic Control, Cardiovascular Risk·PubMed →
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
Ayyaz F, Khan H, Zia I
Intern Emerg Med·2026·Human·PubMed →
Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Amamoo J, Wang Y, Liu H et al.
Adv Ther·2026·Human·PubMed →
Patient characteristics and early experiences with anti-obesity medications: the CAMP study.
Tewksbury C, Soliva EA, Scheffey K et al.
Front Nutr·2026·Human·PubMed →
Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report.
Cho CH, Kim WJ
Korean J Fam Med·2026·Human·PubMed →
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.
AlAraibi AJ, Shakeeb FN, Alqatta T et al.
Nutr Metab Cardiovasc Dis·2026·Human·PubMed →
Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.
Alanizi AH, Alruwythi GM, Alotaibi NH et al.
Front Pediatr·2026·Human·PubMed →
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX.
Chen L, Wang J
Diabetes Care·2026·Human·PubMed →
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.
Odic P, Nardi O, Foucault-Fruchard L
Intern Emerg Med·2026·Human·PubMed →
Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Zhong Y, Tan X, Zhang L et al.
Front Pharmacol·2026·Human·PubMed →
Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.
Giraldi LV, Andersen JT, Jespersen J et al.
BMJ Open·2026·Human·Weight Loss·PubMed →
Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.
Kerr KW, Chang AT, Sulo S et al.
Child Obes·2026·Human·PubMed →
Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.
Moubarak ES, Elgendy MS, Elkoumi O et al.
J Psychopharmacol·2026·Human·PubMed →
Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.
Kassem S
Diabetes Obes Metab·2026·Human·Weight Loss·PubMed →
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
Iwamoto Y, Yamashita K, Seki Y et al.
Endocr J·2026·Human·PubMed →
Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.
Hung CT, An CY, Suk CW et al.
J Asthma Allergy·2026·Human·PubMed →
Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis.
Wu KA, Choudhury A, Wu JA et al.
Knee·2026·Human·PubMed →
Improvement of small fiber neuropathy assessed by corneal confocal microscopy following semaglutide treatment: a case report and literature review.
Anastasiou IA, Tentolouris N, Rebelos E
Hormones (Athens)·2026·Human·PubMed →
Acute pancreatitis following semaglutide therapy: a case report.
Alduraibi RK, Fattouta NA, Altowayan YF
Ann Med Surg (Lond)·2026·Human·PubMed →
Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.
Santos-Pereira M, Frutuoso JF, Pereira SS et al.
Front Endocrinol (Lausanne)·2026·Human·Weight Loss·PubMed →
Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
Patel KS, Fakhoury B, Parmar K et al.
Intest Res·2026·Human·PubMed →
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
Albanese R, Tomaselli F, Berkane Y et al.
Aesthetic Plast Surg·2026·Human·PubMed →
Reduced Risk in Melanoma and Nonmelanoma Skin Cancers in Obese Patients on Semaglutide and Tirzepatide.
Alameddine R, Roecker A, Jabin M et al.
Dermatol Surg·2026·Human·PubMed →
Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.
Tian Z, Willerding JM, Schmidt-Ott KM et al.
EClinicalMedicine·2026·Human·PubMed →
Pharmacist-led medication therapy management improving medication adherence in a patient with type 2 diabetes: case report.
Jiang H, Liu J, Ying Y et al.
Front Med (Lausanne)·2026·Human·PubMed →
Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
Kitsios K, Trakatelli CM
Diabetes Technol Ther·2026·Human·PubMed →
Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.
Burmeister JR, Jawad M, Zazay I et al.
SAGE Open Med Case Rep·2026·Human·PubMed →
Trends in preoperative weight loss modalities among patients receiving body contouring surgery.
Liang J, Anderson JL, Cathey JM et al.
Surg Obes Relat Dis·2026·Human·PubMed →
Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report.
Fougerousse AC
Clin Cosmet Investig Dermatol·2026·Human·PubMed →
Accuracy of Water Intake During Simulated Administration of Oral Semaglutide.
Ketaroonrut N, Jantarapootirat M, Traiwanatham S et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Delays in access to generic semaglutide point to key missing pieces in Canada's drug approval system.
Eisenkraft Klein D, Kesselheim AS
Health Policy·2026·Animal·PubMed →
Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists.
Carson L, Eisner M, Launay C et al.
Skin Health Dis·2026·Animal·PubMed →
Beauty standards and reproductive health: increasing use of GLP-1 receptor agonists despite limited evidence.
de Matos SMS, Faccini LS, Vianna FSL et al.
Front Endocrinol (Lausanne)·2026·Animal·PubMed →
Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.
Husereau D, Evans M, Hahn-Pedersen JH et al.
Value Health·2026·Animal·PubMed →
Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.
Kearney M, Smyth NM, Hassan HSA et al.
Ir Med J·2026·Animal·PubMed →
Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.
Teunis CJ, Collins TJC, Oostveen RF et al.
Eur Heart J·2026·Animal·PubMed →
GLP-1R agonist semaglutide protects human forebrain organoids from cholesterol-induced neurotoxicity.
Yu F, Xu J, Hou Y et al.
Alzheimers Dement·2026·Animal·Neuroprotection·PubMed →
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu, European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)
J Hepatol·2026·Animal·PubMed →
Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.
Wang S, Dong B, Shen Z
Diabetes Ther·2026·Animal·PubMed →
Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.
Mera-Carreiro S, Ramos-Leví A, Matía-Martín P et al.
Obes Surg·2026·Animal·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study.
Bahar F, Karayol E, Lee YC et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
Salim H, Qureshi S, Gulsin GS et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.
Roach KA, Khazaee M, Mohar I et al.
Regul Toxicol Pharmacol·2026·Animal·PubMed →
Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.
Ferician AC, Ghitea TC, Popoviciu MS
Medicina (Kaunas)·2026·Animal·Glycemic Control·PubMed →
Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.
Pavshintsev VV, Erbaeva AZ, Vatlin AA et al.
Biomedicines·2026·Animal·PubMed →
Renal AA amyloidosis associated with severe obesity: improvement in kidney function and proteinuria following semaglutide-associated weight loss.
Atay I, Eroz E, Bayramoğlu Z et al.
J Nephrol·2026·Animal·PubMed →
An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.
Thorne AK, Waldeck NJ, Rose JP et al.
Proc Natl Acad Sci U S A·2026·Animal·Weight Loss·PubMed →